Revance Therapeutics Inc (RVNC)

[DewDiligence]

Foley’s $210K purchase via the underwritten offering is a salve to shareholders for failing to anticipate that the buyers of the third Athyrium tranche would play hardball and put the squeeze on RVNC (#msg-173979843).

This was Foley’s first bona fide mistake in capital management, and his overall track record in this facet of the job remains commendable, IMO.